Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT06893588
Recruiting Observational

Registry on NeVa VS for CerebraL VAsospasm ManagemenT in Post SAH PatiEnts

NCT06893588 · tracked via the Priya Life Science USA tracker
Sponsor
Vesalio
Phase
Observational
Started
2025-04-14
Last updated
2026-05-27

Condition(s) studied

Cerebral VasospasmAneurysmal Subarachnoid Hemorrhage (aSAH)

Investigational drug(s) / intervention(s)

NEVA VS

NEVA VS: cerebral artery dilation device

Study summary

A multi-center, observational registry study intended to assess the HDE-approved NeVa VS cerebral artery dilation device in patients with symptomatic cerebral vasospasm caused by aneurysmal subarachnoid hemorrhage (aSAH)

Eligibility

Sex
ALL
Min age
22 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥22 2. Symptomatic cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage (aSAH) in the internal carotid artery (ICA), middle cerebral artery (MCA), anterior cerebral artery (ACA), posterior cerebral artery (PCA), or basilar artery (BA) 3. Vessel dilation procedure was performed with the NeVa VS 4. Subject or legal representative is able and willing to give informed consent within 3 days (72 hours) post-index procedure Exclusion Criteria: * None

Primary outcome measure(s)

  • Improvement in target vessel diameter following NeVa VS use — Up to 1 hour post procedure

Trial sites (16)

FacilityCityRegionStatus
Providence St. Joseph Medical Center Burbank California Recruiting
John Muir Health Walnut Creek California Recruiting
Yale New Haven Connecticut Recruiting
Baptist Health South Florida Miami Florida Recruiting
Wellstar Health System Marietta Georgia Recruiting
Endeavor Health Evanston Illinois Recruiting
Univ Iowa Iowa City Iowa Recruiting
Univ Kentucky Lexington Kentucky Recruiting
MaineHealth Portland Maine Recruiting
Mayo Clinic- Rochester Rochester Minnesota Recruiting
Allegheny Health Network Pittsburgh Pennsylvania Recruiting
Geisinger Wilkes-Barre Pennsylvania Recruiting
Valley Baptist Medical Center- Harlingen Harlingen Texas Recruiting
University of Texas Health Science Center at Houston Houston Texas Recruiting
Uni. of Utah Salt Lake City Utah Recruiting
West Virginia University Morgantown West Virginia Recruiting

Other trials for the same condition

Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06893588 on ClinicalTrials.gov ↗ ← All trials in the USA